Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database
- 58 Downloads
Off-label use of psychotropic prescriptions for pediatric patients has been increasing in Japan. This study sought to clarify pediatric patients’ off-label use of psychotropics approved only for adults in Japan.
This retrospective study on psychotropic utilization employed a pharmaceutical health insurance claims database supplied by a pharmacy for the fiscal year 2016. Seven psychotropic drugs were examined. For each drug, we calculated the proportion of patients aged < 16 years or who were under the approved age limit set in the United States out of all patients. The maximum daily dose of each drug within the study period was plotted by age.
Data of 45,715 patients (female: 26,799, male: 18,916) with 331,920 prescriptions were examined in this study. For each drug, the proportion of pediatric patients aged < 16 years ranged from 0.15 to 1.1%, while the proportion of those under the approved age limit in the United States ranged from 0 to 0.27%. Olanzapine had the highest reported proportion. No drugs other than olanzapine were taken under the approved age limit in the United States.
We identified the pediatric off-label use of psychotropics that were limited to adult use in Japan. The results indicated the possibility of referring to international guidelines or evidence in clinical practice, but these factors do not discount the existing problems with off-label use. More clinical trials within the pediatric population in Japan are needed to address the issue of off-label use and obtain useful and reliable information in the package inserts for rational use in future pediatric patients.
KeywordsJapan Off-label use Pediatric Prescription Psychotropic drug
We would like to thank Editage (www.editage.jp) for English language editing.
All authors contributed to the design and implementation of this research, the analysis of the results, and writing of the manuscript. All authors approved the final version of the manuscript to be published.
Compliance with ethical standards
The study protocol was approved by the Keio University Faculty of Pharmacy Ethics Committee for research involving humans (No. 170707-1).
Conflict of interest
TS has received speakers’ honoraria from Daiichi Sankyo, Eli Lilly, Glaxo Smith Kline, Novartis, Janssen, Otsuka, Shionogi, Shire, Taisho and Tanabe Mitsubishi, and he has also received research support from Novartis, Otsuka, Shionogi and Taisho (from April 2014 to April 2018). YI is an employee of KRAFT Inc. HU is a consultant of Eisai Co., Ltd. No financial or non-financial benefits have been or will be received by NT, MA and KM from any party related directly or indirectly to the subject of this article.
- 2.Sekimizu M. PMDA’s challenges in pediatric drug development. Regul Sci Med Prod. 2015;5:159–66 (in Japanese).Google Scholar
- 3.Nakagawa M. An unapproved and off-label use in circulatory area for pediatrics. Clin Psychiatry. 2016;79:863–9 (in Japanese).Google Scholar
- 7.Nakamura T. Current status on pediatric drug development tagetted for neuropsychiatric disorder. Jpn J Child Adolescent Psychiatry. 2017;58:76–84 (in Japanese).Google Scholar
- 9.Kuroki S, Seguchi Y, Miyashita S, Uramura K, Yamashita H, Kodaira M. Treatment guidelines for depression at puberty in British and North America. Jpn J Clin Psychiatry. 2011;40:1203–12 (in Japanese).Google Scholar
- 12.Imoto M. Challenges to Unapproved Drugs. Egul Sci Med Prod. 2015;5:121–34 (in Japanese).Google Scholar
- 14.Ozaki M. Industries’ efforts in promoting pediatric drug development. Egul Sci Med Prod. 2015;5:151–8 (in Japanese).Google Scholar
- 19.Ministry of Health, Labour and Welfare. 2014. http://www.mhlw.go.jp/toukei/saikin/hw/kanja/14/index.html. Accessed 31 Mar 2018.
- 20.Nakagome K. Actual condition survey on psychotropic prescription. Tokyo: Health Labour Sciences Research Grant; 2013.Google Scholar
- 22.Ministry of Health, Labour and Welfare. 2017. https://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000153339.pdf. Accessed 1 Apr 2017.
- 23.Meiji Seika Pharma. 2016. https://www.meiji-seika-pharma.co.jp/pressrelease/2016/detail/160328_02.html. Accessed 1 Apr 2018.
- 25.The National Institute for Health and Care Excellence. 2005. https://www.nice.org.uk/guidance/cg28/resources/depression-in-children-and-young-people-identification-and-management-975332810437. Accessed 1 Apr 2018.
- 26.Hughes CW, Emslie GJ, Crismon ML, Posner K, Birmaher B, Ryan N, et al. Texas children’s medication algorithm project: update from texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:667–86.CrossRefPubMedGoogle Scholar
- 28.Yamada K. Guideline on treatment for bipolar disorder. Jpn J Clin Psychopharmacol. 2017;20:541–7 (in Japanese).Google Scholar
- 29.Miyata H, Ishii J. Psychopharmacology of antipsychotic drugs. J Pract Pharm. 2016;67:3186–92 (in Japanese).Google Scholar
- 30.Akiyama K. Pharmacological profile of antipsychotic drug. Clin Psychiatry. 2002;44:238–43 (in Japanese).Google Scholar
- 31.Usami M. Drug therapy with antidepressant in clinical psychiatry for child and adolescence. Jpn J Child Adolesc Psychiatry. 2017;58:146–56 (in Japanese).Google Scholar
- 32.Saito T. Current status on clinical trials tagetted for pediatrics with psychotropic. Jpn J Clin Psychopharmacol. 2013;16:1731–9 (in Japanese).Google Scholar